EASL

Development of a BRAF V600E cholangiocarcinoma model in mice

Fri, 12 Jun 2026 09:00:00 -0400

Researchers from Medizinische Hochschule Hannover and collaborators thus aimed to elucidate signaling adaptations following MAPK pathway inhibition in BRAFV 600E mutant cholangiocarcinoma (CCA) by generating a BRAF V600E-driven model of CCA.

Targeting TRIM54 mitigates liver injury in cirrhosis

Wed, 10 Jun 2026 09:00:00 -0400

Researchers from Beijing University of Chinese Medicine described the role of TRIM54 in cirrhosis progression using two independent animal models of chronic liver injury – a DEN-induced rat model and a CCl4-induced mouse model of liver cirrhosis.

Dual ABCB4/ABCB11 modulation shows promise in cholestatic disease models

Mon, 08 Jun 2026 09:00:00 -0400

Researchers from Rectify Pharmaceuticals Inc. presented preclinical efficacy data on RTY-406, a novel dual-acting ABCB4/MDR3 and ABCB11/BSEP modulator, in animal models of primary sclerosing cholangitis.

FB-7033 demonstrates efficacy in MASH management

Thu, 04 Jun 2026 09:00:00 -0400

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH) progression, where HSD17B13 exacerbates hepatic lipid metabolism, while CIDEB mainly mediates lipid droplet dynamics and storage. In this context, Frontier Biotechnologies Inc. has presented data on FB-7033, a bispecific siRNA approach targeting both HSD17B13 and CIDEB for the management of MASH.

TAK1 emerges as a therapeutic target in MASLD

Wed, 03 Jun 2026 09:00:00 -0400

Transforming growth factor-β-activated kinase 1 (TAK1) is a crucial central signaling molecule of hepatic cell death, inflammation and fibrogenesis through NF-κB and MAPK in metabolic dysfunction-associated steatotic liver disease (MASLD). Its pharmacological inhibition using the TAK1 inhibitor HS-276 was tested in vivo in a murine model of diet-induced MASLD.

GPR119 activation ameliorates alcohol-related liver disease

Wed, 03 Jun 2026 09:00:00 -0400

There is a growing consensus that alcohol-related liver disease (ALD) should be considered a metabolic disorder under the influence of the gut-liver axis. Metabolome data have highlighted fatty acid-activated G protein-coupled receptors (GPCRs) as the main affected pathways, where the relationship of G-protein-coupled receptor 119 (GPR119) with ALD remains unexplored.

ATGL inhibition reshapes immunometabolism in liver fibrosis

Wed, 03 Jun 2026 09:00:00 -0400

Adipose triglyceride lipase (ATGL), a central mediator of triglyceride hydrolysis and fatty acid mobilization, modulates hepatic lipid homeostasis and metabolic signaling pathways that contribute to the activation of fibrogenic responses.

SR-1891 achieves prolonged HBV suppression with one dose

Wed, 03 Jun 2026 09:00:00 -0400

Researchers from Ospedale San Raffaele presented the preclinical characterization of SR-1891, a long-acting capsid assembly modulator (CAM) in models of chronic hepatitis B. In Hepa D38 cells, the compound exhibited EC50 and EC90 values of 0.2 and 0.8 nM, respectively, without any detectable cytotoxicity.

AX-2911 shows in vivo activity by correcting PNPLA3 in MASH

Tue, 02 Jun 2026 09:00:00 -0400

Alterations in PNPLA3, particularly the I148M variant, impair lipid metabolism in hepatocytes, leading to lipid accumulation and driving progression from steatosis to fibrosis and cirrhosis. Targeting this genetic driver may offer a strategy to reduce steatosis and limit disease progression.

PRD-001 shows synergy with Rezdiffra for treating MASH

Tue, 02 Jun 2026 09:00:00 -0400

Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by lipid accumulation in the liver and inflammation. Sterol O-acyltransferase 2 (SOAT2) is a key enzyme in intestinal absorption and hepatic secretion of cholesterol. PRD Therapeutics Inc. has developed PRD-001, a selective SOAT2 inhibitor currently in phase I trials for MASH.

EASL spotlight: TUNE-401 advances epigenetic silencing in HBV

Tue, 02 Jun 2026 09:00:00 -0400

Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most relevant for the novelty it represents and the step forward it signals. The company is investigating the use of TUNE-401 as a potential treatment for hepatitis B.

Targeting UCH-L1 could enhance sorafenib efficacy in HCC

Mon, 01 Jun 2026 09:00:00 -0400

In the treatment of hepatocellular carcinoma (HCC), the long-term benefits of second-line tyrosine kinase inhibitors such as sorafenib are often limited by resistance mechanisms and adverse effects. The deubiquitinase ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is upregulated in advanced HCC disease and has been linked to poor prognosis and treatment resistance.

PLT-012 shows efficacy across different MASH models

Mon, 01 Jun 2026 09:00:00 -0400

Researchers from Pilatus Biosciences SA recently presented preclinical efficacy data for PLT-012, a humanized IgG4 antibody targeting CD36, in metabolic dysfunction-associated steatohepatitis (MASH) models.

EASL 2026: Emerging liver disease targets to watch

Mon, 01 Jun 2026 09:00:00 -0400

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver pathobiology are driving the rapid identification of new druggable targets across diverse indications.

Aligos’ ALG-215007 candidate ASO for HDV infection

Fri, 29 May 2026 09:00:00 -0400

Currently available treatments for chronic hepatitis D virus (HDV) infection rarely result in a cure after a defined treatment period. Researchers from Aligos Therapeutics Inc. hypothesized that antisense oligonucleotides (ASOs) targeting HDV RNAs may inhibit intracellular HDV RNA amplification.

RTY-694 sheds light on treatment of genetic liver disorder

Fri, 29 May 2026 09:00:00 -0400

Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a genetic liver disorder caused by mutations in the ABCB4 gene encoding multidrug resistance protein 3 (MCP3) in humans, a biliary phospholipid transporter. Rectify Pharmaceuticals Inc. has developed the novel compound RTY-694, a dual-acting MDR3/BSEP positive modulator that increased the protein function of both MDR3 and BSEP.

ALG-093940 shows promise for liver cancer and hepatitis B

Fri, 29 May 2026 09:00:00 -0400

Anti-PD-1/PD-L1 therapy has shown success in the treatment of liver cancer and may reverse immune tolerance in chronic hepatitis B (CHB). Aligos Therapeutics Inc. has presented preclinical data on the characterization of ALG-093940, a small molecule PD-1/PD-L1 inhibitor that induces PD-L1 dimerization and degradation.

Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections

Thu, 28 May 2026 12:00:00 -0400

GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense oligonucleotide bepirovirsen.

Oricell’s OriC-902 shows robust results in HCC

Thu, 28 May 2026 09:00:00 -0400

At the ongoing European Association for the Study of the Liver 2026 annual meeting in Barcelona, researchers from Oricell Therapeutics Co. Ltd. presented data on a CAR T-cell approach targeting glypican 3 (GPC3) – OriC-902 – for the treatment of GPC3+ hepatocellular carcinoma (HCC).

EASL 2026: Rebuilding the liver, from organoids to engineered ducts

Thu, 28 May 2026 09:00:00 -0400

With a historic WHO resolution adopted this week giving countries, for the first time, a mandate to address liver disease affecting 1.5 billion people worldwide, this momentum is strongly reflected at the ongoing European Association for the Study of the Liver 2026 congress in Barcelona. The mandate positions liver disease alongside cancer, cardiovascular disease and diabetes as a core global health priority.

KLF15 shows potential as marker, target for cholangiocarcinoma

Tue, 27 Jan 2026 08:00:00 -0500

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in this disease.

Study identifies CAND1 as therapeutic target in hepatoblastoma

Mon, 26 Jan 2026 08:00:00 -0500

Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a post-translational modification that modulates cullin-RING ligases and has arisen as a crucial regulator of protein turnover in cancer.

Madrigal is the NASH/MASH master … of the moment

Tue, 18 Jun 2024 09:15:00 -0400

For the time being, Madrigal Pharmaceuticals Inc.’s Rezdiffra (resmetirom) stands alone as the only U.S. FDA approved treatment for treating nonalcoholic steatohepatitis (NASH). But new and positive data from multiple companies show Madrigal may soon have company.

Conference data for July 11, 2023: EASL

Tue, 11 Jul 2023 12:00:00 -0400

New and updated clinical data presented by biopharma firms at the European Association for the Study of the Liver Congress, including: Arrowhead, Takeda.

Sequana reports promising results for its automatic pump to control ascites

Wed, 05 Jul 2023 12:00:00 -0400

Sequana Medical NV has reported additional data on safety, survival and quality of life from its POSEIDON pivotal study in North America, evaluating its Alfapump device used in the treatment of patients with recurrent or refractory ascites caused by liver cirrhosis. The data were recently presented at the European Association for the Study of the Liver 2023 congress in Vienna.

Conference data for June 27, 2023: EASL

Tue, 27 Jun 2023 12:00:00 -0400

New and updated clinical data presented by biopharma firms at the European Association for the Study of the Liver Congress, including: 89bio, Arrowhead, Mirum, Takeda, Vir.

Conference data for June 29, 2022: EASL

Wed, 29 Jun 2022 11:00:00 -0400

New and updated preclinical and clinical data presented by biopharma firms at the EASL International Liver Congress, including: Eiger.

Conference data for June 28, 2022: EASL

Tue, 28 Jun 2022 11:00:00 -0400

New and updated preclinical and clinical data presented by biopharma firms at the EASL International Liver Congress, including: Antios, Ascletis, Chemomab, Immunocore, Ionis, Mirum.

Phase III data from Gilead’s hepatitis D ‘cure’ and Madrigal’s NASH hopeful take center stage at ILC

Mon, 27 Jun 2022 12:00:00 -0400

New data confirming that Gilead Sciences Inc.’s Hepcludex (bulevirtide) effectively cures hepatitis delta virus (hepatitis D), one of the most severe viral infections of the liver, and favorable phase III results from Madrigal Pharmaceuticals Inc.’s nonalcoholic steatohepatitis (NASH) contender were among the highest-profile scientific announcements at the International Liver Congress (ILC) 2022.

Conference data for June 28, 2021: EASL

Mon, 28 Jun 2021 11:00:00 -0400

New and updated preclinical and clinical data presented by biopharma firms at The International Liver Congress – The Annual Meeting of the European Association for the Study of the Liver, including: Arbutus, Arrowhead.